Results 1 to 10 of about 1,141 (182)

Clinical Case Report on the Use of Rezafungin in Pneumocystis jirovecii Pneumonia in a Critically Ill Patient [PDF]

Microorganisms
Pneumocystis jirovecii pneumonia (PJP) is a life-threatening opportunistic infection predominantly affecting immunocompromised patients. Trimethoprim–sulfamethoxazole (TMP–SMX) remains the standard therapy but is often limited by severe toxicity ...
Rosario Fernández-Fernández, Roberto García-Martínez, Waldo Sánchez-Yebra Fernández, Natalia Chueca-Porcuna, Manuel Colmenero-Ruiz   +4 more
doaj   +2 more sources

The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis [PDF]

Infection and Drug Resistance
Anna Zubovskaia, Jose A Vazquez Division of Infectious Diseases, Department of Medicine, Wellstar MCG/Augusta University, Augusta, GA, USACorrespondence: Jose A Vazquez, Division of Infectious Diseases, Department of Medicine, Wellstar MCG/Augusta ...
Zubovskaia A, Vazquez JA
doaj   +2 more sources

Anidulafungin is a useful surrogate marker for predicting in vitro susceptibility to rezafungin among five Candida species using CLSI methods and interpretive criteria [PDF]

Journal of Clinical Microbiology
This study addresses the use of other echinocandins as surrogate markers to predict the susceptibility of rezafungin against the six most common Candida spp.
Marisa L. Winkler, Lalitagauri Deshpande, John H. Kimbrough, Maura Karr, Paul Rhomberg, Abby L. Klauer, Mariana Castanheira   +6 more
doaj   +2 more sources

Necrotizing gingival infection due to in an hematopoietic stem cell transplant recipient: case report [PDF]

Therapeutic Advances in Infectious Disease
Trichoderma is a genus of rare filamentous fungi that can cause invasive fungal infections in immunocompromised patients. We report a case of necrotizing gingival and sinus infection due to T.
Eduardo Aparicio-Minguijón, Nieves López-Muñoz, Pilar Martínez-Sánchez, María Calbacho, Ana Pérez-Ayala, Justino Jiménez-Almonacid, María Asunción Pérez-Jacoiste Asín, Isabel Rodríguez-Goncer   +7 more
doaj   +2 more sources

The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics. [PDF]

J Antimicrob Chemother
Echinocandin drugs are the current first-line therapy for fungal infections caused by Candida spp. Most patients require once-daily intravenous (IV) administration in a hospital or outpatient setting for treatment, which may negatively impact their ...
Andes D, Brüggemann RJ, Flanagan S, Lepak AJ, Lewis RE, Ong V, Rubino CM, Sandison T.   +7 more
europepmc   +3 more sources

Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials. [PDF]

Crit Care
BACKGROUND: Rezafungin is an echinocandin approved in the US and EU to treat candidaemia and/or invasive candidiasis. This post-hoc, pooled analysis of the Phase 2 STRIVE and Phase 3 ReSTORE trials assessed rezafungin versus caspofungin in patients with ...
Honoré PM, Girardis M, Kollef M, Cornely OA, Thompson GR, Bassetti M, Soriano A, Huang H, Vazquez J, Kullberg BJ, Pappas PG, Manamley N, Sandison T, Pullman J, Nseir S.   +14 more
europepmc   +3 more sources

Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials [PDF]

Lancet Infectious Diseases, The
BACKGROUND: Rezafungin, a new US Food and Drug Administration-approved, long-acting echinocandin to treat candidaemia and invasive candidiasis, was efficacious with a similar safety profile to caspofungin in clinical trials.
George R Thompson 3rd, Alex Soriano, Patrick M Honore   +2 more
exaly   +3 more sources

High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies [PDF]

Microorganisms
Invasive fungal diseases (IFDs) still represent a relevant cause of mortality in patients affected by hematological malignancies, especially acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) undergoing remission induction chemotherapy, and
Giovanni Mori, Sara Diotallevi, Francesca Farina, Riccardo Lolatto, Laura Galli, Matteo Chiurlo, Andrea Acerbis, Elisabetta Xue, Daniela Clerici, Sara Mastaglio, Maria Teresa Lupo Stanghellini, Marco Ripa, Consuelo Corti, Jacopo Peccatori, Massimo Puoti, Massimo Bernardi, Antonella Castagna, Fabio Ciceri, Raffaella Greco, Chiara Oltolini   +19 more
doaj   +3 more sources

Tn-seq screens in Candida glabrata treated with echinocandins and ibrexafungerp reveal pathways of antifungal resistance and cross-resistance [PDF]

mSphere
Candida glabrata (also known as Nakaseomyces glabratus) is the second most common cause of candidiasis, next to Candida albicans, and is rising in prevalence due to intrinsic and acquired mechanisms of antifungal resistance.
Timothy J. Nickels, Kyle W. Cunningham
doaj   +2 more sources

Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin [PDF]

, 2023
Introduction: Invasive Candida Infections (ICIs) have undergone a series of significant epidemiological, pathophysiological, and clinical changes during the last decades, with a shift toward non-albicans species, an increase in the rate of exogenous ...
De Rosa, Francesco Giuseppe, Mikulska, Malgorzata, Oliva, Alessandra, Pea, Federico, Sanguinetti, Maurizio, Tascini, Carlo, Venditti, Mario   +6 more
core   +8 more sources